8-K: NeuroPace Announces Mixed but Promising One-Year NAUTILUS Study Results for Generalized Epilepsy, Reaffirms 2025 Financial Guidance

NeuroPace, Inc. announced preliminary one-year data from its NAUTILUS study for drug-resistant idiopathic generalized epilepsy, meeting safety endpoints and showing significant effectiveness in a key patient subgroup, while reaffirming its full-year 2025 financial guidance.

Summary

• NeuroPace, Inc. announced preliminary one-year results from the NAUTILUS study, evaluating the RNS System for drug-resistant idiopathic generalized epilepsy (IGE).
• The study successfully met its primary 12-week post-implant safety endpoint, demonstrating a low rate of serious adverse events consistent with the RNS System's established safety profile.
• The primary effectiveness endpoint, which aimed to show a longer time to a second generalized tonic-clonic seizure, did not reach statistical significance in the overall study population.
• However, a clinically meaningful and highly statistically significant response in the primary effectiveness endpoint was observed within a subgroup of patients with lower baseline frequency of generalized tonic-clonic seizures, representing the majority of trial participants.
• Preliminary data at one-year illustrated more favorable rates of median seizure reduction than observed in the Company's randomized controlled trial for focal epilepsy that led to FDA approval.
• The Company reaffirmed its previously issued full-year 2025 financial guidance.
• NeuroPace received FDA Breakthrough Device Designation status in 2021 for the potential use of its RNS System to treat IGE.
• Patients in the NAUTILUS trial will continue participation through the completion of two years after device implant.
• The Company plans to submit the full dataset to the FDA and for peer-reviewed publication, and will engage with the FDA to discuss regulatory pathways, including potential targeted indications.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While the primary effectiveness endpoint was not met for the overall study population, the strong positive results in a significant subgroup, coupled with positive safety data, robust secondary endpoints, and reaffirmed financial guidance, suggest a favorable strategic path forward for the company, despite the technical miss on the overall primary endpoint.

Positives

• The NAUTILUS study successfully met its primary 12-week post-implant safety endpoint, demonstrating excellent safety outcomes and confirming the favorable safety profile of the RNS System.
• A clinically meaningful and highly statistically significant response in the primary effectiveness endpoint was observed within a subgroup of patients with lower baseline frequency of generalized tonic-clonic seizures, which represented the majority of trial participants.
• Preliminary data at one-year illustrates the overall value of the RNS System to individualize patient treatment over time, showing more favorable rates of median seizure reduction than observed in the Company's randomized controlled trial supporting its current indication in focal epilepsy.
• Clinically relevant data, including median percent seizure reduction, responder rates, and improvement in seizure-free days, showed numerically robust and clinically meaningful improvements over the first year of treatment in the entire trial population.
• Preliminary metrics showed continued clinical improvement over time in patients who have completed more than 12 months in the study, aligning with prior findings from the RNS System in the focal epilepsy population.
• NeuroPace reaffirmed its full-year 2025 financial guidance, indicating stability in its financial outlook.
• The CEO noted a strong base business growing over 20% year over year.
• The RNS System received FDA Breakthrough Device Designation status in 2021 for IGE, highlighting its potential significance.

Negatives

• The primary effectiveness endpoint did not reach statistical significance in the overall study population for the NAUTILUS study.

Risks

• Actual operating results may differ significantly from any guidance provided.
• Uncertainties exist related to market acceptance and adoption of NeuroPace's RNS System and potential impacts to revenue for 2025 and in the future.
• Operating expenses could be higher than anticipated, potentially leading to faster usage of cash resources.
• Gross margin may be lower than forecast.
• Risks are present related to the pricing of the RNS System and the availability of adequate reimbursement for implant procedures and ongoing patient care.
• Risks are associated with regulatory compliance and expectations for regulatory submissions and approvals to expand the market for the RNS System.
• Risks related to clinical development, including the potential for unfavorable or inconsistent clinical data from ongoing clinical studies.

Future Outlook

NeuroPace plans to submit the full dataset from the NAUTILUS study to the FDA and for peer-reviewed publication. The company will engage with the FDA to discuss regulatory pathways, potentially utilizing overall median seizure reduction data across the full study population or pursuing a more targeted indication focused on patients with lower baseline seizure frequency. Management expressed confidence in the potential for future indication expansion into IGE and in their long-term growth strategy.

Management Comments

• Dr. Martha Morrell, Chief Medical Officer: "We are very encouraged by the NAUTILUS study results, which demonstrated statistically significant seizure reduction in a key and substantial patient subgroup along with durable improvements across multiple secondary endpoints."
• Dr. Martha Morrell, Chief Medical Officer: "These findings further validate the RNS Systems ability to provide personalized therapy, especially when compared to our focal epilepsy pivotal trial that led to our initial approval, while also reinforcing our commitment to expanding access to RNS therapy."
• Dr. Martha Morrell, Chief Medical Officer: "We are pleased with the results to date and are confident in our potential for future indication expansion into IGE, as we continue our engagement with the U.S. Food and Drug Administration."
• Joel Becker, Chief Executive Officer: "We view the totality of the data in the NAUTILUS study as a meaningful catalyst that adds to the growing body of evidence and momentum in our business."
• Joel Becker, Chief Executive Officer: "With a strong base business growing over 20% year over year, we remain confident in our long-term growth strategy and excited by the opportunity ahead."

Industry Context

NeuroPace operates in the medical device industry, specializing in neuromodulation for epilepsy. The RNS System is a unique brain-responsive platform that delivers personalized, real-time treatment. The NAUTILUS study's focus on idiopathic generalized epilepsy (IGE) addresses a significant unmet need for patients with drug-resistant forms of this severe condition. The FDA Breakthrough Device Designation for IGE underscores the potential for the RNS System to transform care in this patient population, positioning NeuroPace at the forefront of advanced epilepsy treatment technologies.

Comparison to Industry Standards

• The document states that preliminary data at one-year from the NAUTILUS study showed more favorable rates of median seizure reduction than observed in the Company's own randomized controlled trial for focal epilepsy that led to FDA approval. No specific comparisons to other companies, projects, or global industry benchmarks were provided in the document.

Stakeholder Impact

• Shareholders: The mixed clinical trial results (missed overall primary endpoint but strong subgroup data) could introduce short-term volatility, but the reaffirmed guidance and potential for future indication expansion into IGE offer long-term growth prospects.
• Patients with Drug-Resistant IGE: The study results, particularly for the majority subgroup, suggest a potential new and effective treatment option for a severe and debilitating condition, offering hope for improved seizure control.
• Clinicians: The data provides further evidence of the RNS System's efficacy and safety, potentially expanding its utility to a new patient population (IGE), which could influence treatment protocols and patient referrals.
• Employees: Continued clinical development and potential market expansion could lead to job stability and growth opportunities within the company.

Next Steps

• Patients enrolled in the NAUTILUS study will continue to participate through the completion of two years after the device implant, with prespecified collection of safety and effectiveness data.
• NeuroPace plans to submit the full dataset from the NAUTILUS study to the FDA and for peer-reviewed publication.
• The Company will engage with the FDA to discuss regulatory pathways based on the data.
• Discussions with the FDA may include the possibility of utilizing the overall median seizure reduction data across the full study population.
• Discussions with the FDA may also include pursuing a more targeted indication focused on patients with lower baseline seizure frequency who may represent a majority of patients with IGE.

Key Dates

Recommendation

Keywords

NeuroPace, NPCE, RNS System, Epilepsy, Idiopathic Generalized Epilepsy, IGE, Drug-resistant epilepsy, Neuromodulation, Medical Device, Clinical Trial, NAUTILUS study, FDA Breakthrough Device, Seizure reduction, Financial Guidance